E
Eric Cober
Researcher at Cleveland Clinic
Publications - 40
Citations - 1678
Eric Cober is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Carbapenem-resistant enterobacteriaceae & Klebsiella pneumoniae. The author has an hindex of 17, co-authored 35 publications receiving 1148 citations.
Papers
More filters
Journal ArticleDOI
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
David van Duin,Judith J. Lok,Michelle Earley,Eric Cober,Sandra S. Richter,Federico Perez,Federico Perez,Robert A. Salata,Robert C. Kalayjian,Richard R. Watkins,Richard R. Watkins,Yohei Doi,Keith S Kaye,Vance G. Fowler,David L. Paterson,Robert A. Bonomo,Robert A. Bonomo,Scott R. Evans +17 more
TL;DR: Ceftazidime-avibactam may be a reasonable alternative to colistin in the treatment of K. pneumoniae carbapenemase-producing CRE infections and require confirmation in a randomized controlled trial.
Journal ArticleDOI
Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality.
Laura J. Rojas,Laura J. Rojas,Madiha Salim,Eric Cober,Sandra S. Richter,Federico Perez,Federico Perez,Robert A. Salata,Robert C. Kalayjian,Richard R. Watkins,Richard R. Watkins,S H Marshall,Susan D. Rudin,T. Nicholas Domitrovic,Andrea M. Hujer,Kristine M. Hujer,Yohei Doi,Keith S. Kaye,Scott R. Evans,Vance G. Fowler,Robert A. Bonomo,David van Duin +21 more
TL;DR: The apparent polyclonal nature of the isolates suggests de novo emergence of ColR in this cohort as the primary factor driving ColR, and mortality was increased in patients with ColR isolates.
Journal ArticleDOI
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study
David van Duin,Cesar A. Arias,Lauren Komarow,Liang Chen,Blake Hanson,Gregory Weston,Eric Cober,Omai B. Garner,Jesse T. Jacob,Michael J. Satlin,Bettina C. Fries,Julia Garcia-Diaz,Yohei Doi,Sorabh Dhar,Keith S Kaye,Michelle Earley,Andrea M. Hujer,Kristine M. Hujer,T. Nicholas Domitrovic,William C Shropshire,An Dinh,Claudia Manca,Courtney L Luterbach,Minggui Wang,David L. Paterson,Ritu Banerjee,Robin Patel,Scott R. Evans,Carol Hill,Rebekka M. Arias,Henry F. Chambers,Vance G. Fowler,Barry N. Kreiswirth,Robert A. Bonomo +33 more
TL;DR: Among patients with CDC-defined CRE, similar outcomes were observed among three subgroups, including the novel unconfirmed CRE group, and the primary outcome was desirability of outcome ranking (DOOR) at 30 days after index culture.
Journal ArticleDOI
Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional Network
David van Duin,Federico Perez,Federico Perez,Susan D. Rudin,Eric Cober,Jennifer A. Hanrahan,Julie Ziegler,Raymond Webber,Jacqueline Fox,Pamela Mason,Sandra S. Richter,Marianne Cline,Geraldine S. Hall,Keith S. Kaye,Michael R. Jacobs,Robert C. Kalayjian,Robert A. Salata,Julia A. Segre,Sean Conlan,Scott R. Evans,Vance G. Fowler,Robert A. Bonomo +21 more
TL;DR: In this paper, a regional network was established to study microbiological and genetic determinants of clinical outcomes in hospitalized patients with carbapenem-resistant (CR) Klebsiella pneumoniae in a prospective, multicenter, observational study.
Journal ArticleDOI
Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections☆
Christopher G. Hauck,Eric Cober,Sandra S. Richter,Federico Perez,Robert A. Salata,Robert C. Kalayjian,Richard R. Watkins,Nikole M. Scalera,Yohei Doi,Keith S. Kaye,Scott R. Evans,Vance G. Fowler,Robert A. Bonomo,D. van Duin +13 more
TL;DR: In patients with CRKp infection, pneumonia is associated with the highest excess hospital mortality, according to the Consortium on Resistance against Carbapenems in K. pneumoniae (CRACKLE), a prospective multicenter study.